skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 6,912  for All Library Resources

Results 1 2 3 4 5 next page
Refined by: subject: Cancer Therapies remove subject: Patients remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial
Material Type:
Article
Add to My Research

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial

The lancet oncology, 2019-03, Vol.20 (3), p.352-360 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 2019 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30813-1 ;PMID: 30711522

Full text available

2
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Material Type:
Article
Add to My Research

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

The lancet oncology, 2021-09, Vol.22 (9), p.1275-1289 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00342-9

Full text available

3
The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis
Material Type:
Article
Add to My Research

The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis

JNCI : Journal of the National Cancer Institute, 2022-03, Vol.114 (3), p.391-399 [Peer Reviewed Journal]

The Author(s) 2021. Published by Oxford University Press. 2021 ;The Author(s) 2021. Published by Oxford University Press. ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djab202 ;PMID: 34747484

Full text available

4
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Material Type:
Article
Add to My Research

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

The lancet oncology, 2018-07, Vol.19 (7), p.904-915 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30292-4 ;PMID: 29804902

Full text available

5
Triple-negative breast cancer molecular subtyping and treatment progress
Material Type:
Article
Add to My Research

Triple-negative breast cancer molecular subtyping and treatment progress

Breast cancer research : BCR, 2020-06, Vol.22 (1), p.1-61, Article 61 [Peer Reviewed Journal]

COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1465-542X ;ISSN: 1465-5411 ;EISSN: 1465-542X ;DOI: 10.1186/s13058-020-01296-5 ;PMID: 32517735

Full text available

6
HER2-positive breast cancer
Material Type:
Article
Add to My Research

HER2-positive breast cancer

The Lancet (British edition), 2017-06, Vol.389 (10087), p.2415-2429 [Peer Reviewed Journal]

Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 17, 2017 ;2017. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)32417-5 ;PMID: 27939064

Full text available

7
Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial
Material Type:
Article
Add to My Research

Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial

The Lancet (British edition), 2019-11, Vol.394 (10211), p.1807-1815 [Peer Reviewed Journal]

2019 Elsevier Ltd ;2019. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)32313-X

Full text available

8
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Material Type:
Article
Add to My Research

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

The lancet oncology, 2021-08, Vol.22 (8), p.1139-1150 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 1470-2045 ;ISSN: 1474-5488 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00288-6 ;PMID: 34339645

Full text available

9
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Material Type:
Article
Add to My Research

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

The New England journal of medicine, 2018-07, Vol.379 (2), p.111-121 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1804710 ;PMID: 29860917

Full text available

10
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
Material Type:
Article
Add to My Research

Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study

The lancet oncology, 2018-07, Vol.19 (7), p.880-888 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30256-0 ;PMID: 29804905

Full text available

11
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Material Type:
Article
Add to My Research

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2018-01, Vol.19 (1), p.87-100 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2018 Elsevier B.V. ;Copyright Elsevier Limited Jan 1, 2018 ;2018. Elsevier Ltd ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30688-5 ;PMID: 29223745

Full text available

12
Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients
Material Type:
Article
Add to My Research

Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients

The lancet oncology, 2018-03, Vol.19 (3), p.337-346 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2018 ;2018. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30059-7 ;PMID: 29395867

Full text available

13
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
Material Type:
Article
Add to My Research

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

The Lancet (British edition), 2019-04, Vol.393 (10179), p.1440-1452 [Peer Reviewed Journal]

2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2019. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)33137-4 ;PMID: 30739743

Full text available

14
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Material Type:
Article
Add to My Research

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

The New England journal of medicine, 2016-11, Vol.375 (18), p.1738-1748 [Peer Reviewed Journal]

Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1609709 ;PMID: 27717303

Full text available

15
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Material Type:
Article
Add to My Research

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

The New England journal of medicine, 2016-08, Vol.375 (8), p.717-729 [Peer Reviewed Journal]

Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1602253 ;PMID: 27557300

Full text available

16
Breast Cancer Treatment
Material Type:
Article
Add to My Research

Breast Cancer Treatment

American family physician, 2021-08, Vol.104 (2), p.171-178 [Peer Reviewed Journal]

Copyright American Academy of Family Physicians Aug 01, 2021 ;ISSN: 0002-838X ;EISSN: 1532-0650

Full text available

17
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Material Type:
Article
Add to My Research

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

The New England journal of medicine, 2018-07, Vol.379 (4), p.341-351 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1805131 ;PMID: 29863979

Full text available

18
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Material Type:
Article
Add to My Research

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

The New England journal of medicine, 2019-07, Vol.381 (4), p.307-316 [Peer Reviewed Journal]

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1903765 ;PMID: 31166679

Full text available

19
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Material Type:
Article
Add to My Research

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

The lancet oncology, 2018-03, Vol.19 (3), p.295-309 [Peer Reviewed Journal]

2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license ;Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2018 ;2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30079-2 ;PMID: 29449189

Full text available

20
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Material Type:
Article
Add to My Research

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2019-03, Vol.20 (3), p.339-351 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 2019 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30862-3 ;PMID: 30795951

Full text available

Results 1 - 20 of 6,912  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 1988  (17)
  2. 1988 To 1996  (57)
  3. 1997 To 2005  (213)
  4. 2006 To 2015  (1,083)
  5. After 2015  (5,543)
  6. More options open sub menu

Subject 

  1. Womens Health  (6,804)
  2. Breast Cancer  (4,498)
  3. Chemotherapy  (3,269)
  4. Science & Technology  (3,082)
  5. Oncology  (2,906)
  6. Life Sciences & Biomedicine  (2,768)
  7. Tumors  (1,864)
  8. Metastasis  (1,771)
  9. Surgery  (1,670)
  10. Humans  (1,560)
  11. Female  (1,462)
  12. Medical Prognosis  (1,433)
  13. Cancer  (1,424)
  14. Clinical Trials  (1,407)
  15. Medical Research  (1,344)
  16. Radiation Therapy  (1,259)
  17. Hospitals  (1,180)
  18. Ovarian Cancer  (1,078)
  19. More options open sub menu

Language 

  1. English  (6,911)
  2. Japanese  (185)
  3. Turkish  (11)
  4. Portuguese  (5)
  5. Chinese  (5)
  6. Norwegian  (4)
  7. French  (2)
  8. German  (1)
  9. More options open sub menu

Searching Remote Databases, Please Wait